北京1946生物技术有限公司_韦德国际源于1946 北京1946生物技术有限公司_韦德国际源于1946
道培客户端数据
非血缘案例
1195
亲缘半相同案例
4859
源于案例
7331

陆佩华 /app客户端执行客户端、美国1946病及肿瘤内科专家

客户端:app客户端执行客户端、清华大学(国际院)— 北京19461946病研究院客户端 。

擅长:1946客户端手机、淋巴瘤、1946瘤及手机等的研究及手机。


星期  
坐诊时间:【周一至周五(需提前电话预约)】
  • 医生履历
  • 科研荣誉
  • 学术论文
  • 北京国际院毕业后赴美,后获得在美行医许可。在美任住院医后,以杰出的成绩被斯坦福大学国际中心1946病及肿瘤专科录取为1946Fellow,取得1946病及肿瘤专家资格。先后获得了美国国立卫生研究院(NIH)的两个奖包括个人的博士后研究奖及医生科学家奖(KO11)。研究了具有抗肿瘤客户端功能的Cytokine Induced Killer (CIK) Cells,在动物实验上抗肿瘤功能显著。后被引入中国应用于1946手机,是国内最早开展的几项1946客户端手机之一。曾应美国国家国际会邀请在年会上报告个人在美成功奋斗历程。于2012年被美国消费者协会评选为美国杰出的1946病及肿瘤专家。具有美国1946病专科医师,肿瘤专科医生执照以及中国行医执照。

    于2015年回国,回国后主导了多项工作及研究,现任中国非公客户端协会第一届常务理事、中国非公立客户端机构协会1946病专业委员会主任委员、中国非公立客户端机构协会生物技术与1946应用专业委员会常务委员、中国app捐献者资料库专家委员会委员、中国1946肿瘤学会(CSCO)抗手机联盟专家委员会常务委员、中国抗癌协会第一届1946病转化国际专业委员会常务委员。在1946客户端手机如CAR-T手机、淋巴瘤、1946瘤及手机等多领域有深入的研究及丰富的1946经验。

    5b0781b7ee960.jpg

    Lu, P. H., Negrin, R.S. A novel population of expanded human CD3+, CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

    J. Immunol. 1994 153;1687.

    Lu, P.H., Negrin, R.S. Cellular immunotherapy following autologous hematopoietic progenitor transplantation.

    Biol Blood Marrow Transplant, 1997, 3(3);113-21.

    Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL, Liu SH, Wu T, Lu PH, Lu DP, Chang AH, Tong CR.High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

    Leukemia, 2017 Dec;31(12):2587-2593. doi: 10.1038/leu.2017.145. Epub 2017 May 15.

    Yang Zhang, Fang Wang, Xue Chen, Yu Zhang, Mingyu Wang, Hong Liu, Panxiang Cao, Xiaoli Ma, Tong Wang, Jianping Zhang, Xian Zhang, Peihua Lu#, and Hongxing Liu#.CSF3R mutations are frequently associated with abnormalities of RUNX1, CBFB,CEBPA, and NPM1 genes in acute myeloid leukemia.

    Cancer, 2018 Aug;124(16):3329-3338. doi: 10.1002/cncr.31586. Epub 2018 Jun 22.

    Saleem MS, Aljurf M, Srivastava A, Shamsi T, Lu PH, Hamidieh AA, El Haddad A, Hashmi SK. Challenges in managing graft-versus-host disease in developing countries: a perspective.

    Bone Marrow Transplant, 2018 Sep 20. doi: 10.1038/s41409-018-0333-z. [Epub ahead of print]

    Abstract:

    Lu, P.H. Negrin, R.S. Interleukin-12 promotes the expansion of CD3+CD56+ killer cells derived from CD3+CD56- T cells with enhanced cytotoxicity.

    Blood, 1994, Vol 84, No 10, Suppl: pp289a

    Lu, P.H. Negrin, R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

    Blood, 1993, Vol 82, No 10, Suppl:pp188a (oral presentation at ASH in Dec.1993)

    Lu, P.H. Wang, Z and Negrin, R.S. Functional properties of clonal populations of CD3+CD56+ cells.  

    Blood, 1996, Vol 88, No 10, Suppl:pp42b.

    Lu, P.H. Wang, Z, Mehta, B and Negrin, R.S. Role of IL-12 and IL-15 in the ex vivo expansion, cytotoxicity and cytokine production of human CD3+CD56+ cells derived from T cells.

    Blood, 1996, Vol 88, No 10, Suppl:pp316a.

    Wang, Z, Lu, P.H. Weiner, G, Tso, Jand Negrn, R.S. Anti-CD3 X anti-1D10 bispecific antibody retargets and enhances the cytotoxicity of cytokine induced killer cells.

    Blood, 1996, Vol, No 1,Suppl:pp316a.

    Biping Deng, Alex Hongsheng Chang, Junfang Yang, Jing Pan, Xian Zhang, Yuehui Lin, Yanan Wu, Zhenling Deng, Peihua Lu, Tong Wu, Zhaoli Liu, Chunrong Tong. Safety and efficacy of low dose CD19-CART therapy in 47 cases with relapsed refractory B-cell acute lymphoblastic leukemia(B-ALL).

    ASH, December 3-6, 2016, oral presentation.

    Xian Zhang1*, Xin-An Lu2*, Min Xiong1, Jun-Fang Yang1, Jian-Ping Zhang1, Xiao-Su Zhou1, Ting He2#, Pei-Hua Lu1#, Safety and efficacy of autologous or donor-derived CD19 CAR-T Treatment in relapsed B acute lymphocytic leukemia after Allo-HSCT.

    EBMT, March 18-21,2018, oral presentation.

    Junfang Yang1*, Xin-An Lu2*, Xian Zhang1, Min Xiong1, Jian-Ping Zhang1, Xiao-Su Zhou1, Fei-fei Qi2, Ting He2#, Pei-Hua Lu1#, Comparison of CD19 CAR-T cells with distinct co-stimulatory domains in treatment of B-cell acute lymphoblastic leukemia.

    ASCO, June 1-5,2018, presentation in the Poster Session.

    Junfang Yang, Jianqiang Li, Xian Zhang, Fanyong Lv,  Xiaoling Guo, Qinglong Wang,Lin Wang,Dandan Chen,Xiaosu Zhou, Jinhai Ren, Peihua Lu#, A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia.

    ASH, December 1-4, 2018, oral presentation.

    Xian Zhang, Xin-an Lu, Junfang Yang, Fanyong Lv, Min Xiong, Jianping Zhang, Xiaosu Zhou, Ting He, Peihua Lu#
,Efficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden(HLB), BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse.

    ASH, December 1-4, 2018, oral presentation.

  • 对于罹患1946病的app而言,精准、个体化的1946...【详细】
    4月3日下午,“1946病app康复训练”的健康宣...【详细】
     
    中华人民共和国卫生部
    中华1946库
    1946病专科医协体
    湖北省1946库
    千亿国际德赢官网betway体育注册